File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Presence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer
Title | Presence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer |
---|---|
Authors | |
Issue Date | 2011 |
Publisher | Churchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast |
Citation | The 12th International Conference Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 15-19 March 2011. In The Breast, 2011, v. 20, suppl. 1, p. S39, article no. P182 How to Cite? |
Abstract | GOALS: We have previously shown that primary breast invasive ductal carcinoma co-existing with ductal-carcinoma-in-situ (IDC-DCIS) is characterized by lower proliferation rate and metastatic propensity than sizematched pure IDC, especially if the ratio of DCIS to IDC size is high. On the other hand, IDC-DCIS is more often ER-positive, PR-positive and/or HER2-positive than is pure IDC. This analysis aims to clarify whether the presence of co-existing DCIS in IDC affects tumor aggressiveness in various biological subtypes of breast cancer respectively. METHODS: Tumor data obtained from 1355 consecutive female patients undergoing upfront surgery for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into 4 groups: (i) luminal A (ER and/or PR-positive, HER2-negative, Ki67_12), (ii) luminal B (ER and/or PR-positive, HER2-negative, Ki67 > 12), (iii) HER2 (HER2-positive) and (iv) basal-like (triple-negative) disease. Ki67 expression and nodal involvement of IDC with or without DCIS in these groups were compared. RESULTS: The number of patients with luminal A, luminal B, HER2 and basal-like breast cancer were 458, 315, 247 and 128 respectively. Ki-67 was lower in IDC-DCIS than in size-adjusted pure IDC of both luminal A and luminal B subtypes (p = 0.15 and <0.005 respectively). Pure IDC of these biological subtypes were also associated with more advanced lymph node status as compared to IDC-DCIS, although not statistically significant. In HER2 or basal-like tumors, there were no significant difference between pure IDC and IDC-DCIS. CONCLUSION: The presence of co-existing DCIS in IDC predicts lower biological aggressiveness in luminal cancers but not in the conventionally more aggressive HER2-positive and triple-negative subtypes. |
Description | Poster Session 1 - Predictive and prognostic factors |
Persistent Identifier | http://hdl.handle.net/10722/136109 |
ISSN | 2023 Impact Factor: 5.7 2023 SCImago Journal Rankings: 1.688 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong, H | en_US |
dc.contributor.author | Leung, RCY | en_US |
dc.contributor.author | Lau, S | en_US |
dc.contributor.author | Chiu, J | en_US |
dc.contributor.author | Cheung, P | en_US |
dc.contributor.author | Wong, T | en_US |
dc.contributor.author | Liang, R | en_US |
dc.contributor.author | Epstein, R | en_US |
dc.contributor.author | Yau, T | en_US |
dc.date.accessioned | 2011-07-27T02:02:58Z | - |
dc.date.available | 2011-07-27T02:02:58Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | The 12th International Conference Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 15-19 March 2011. In The Breast, 2011, v. 20, suppl. 1, p. S39, article no. P182 | en_US |
dc.identifier.issn | 0960-9776 | - |
dc.identifier.uri | http://hdl.handle.net/10722/136109 | - |
dc.description | Poster Session 1 - Predictive and prognostic factors | - |
dc.description.abstract | GOALS: We have previously shown that primary breast invasive ductal carcinoma co-existing with ductal-carcinoma-in-situ (IDC-DCIS) is characterized by lower proliferation rate and metastatic propensity than sizematched pure IDC, especially if the ratio of DCIS to IDC size is high. On the other hand, IDC-DCIS is more often ER-positive, PR-positive and/or HER2-positive than is pure IDC. This analysis aims to clarify whether the presence of co-existing DCIS in IDC affects tumor aggressiveness in various biological subtypes of breast cancer respectively. METHODS: Tumor data obtained from 1355 consecutive female patients undergoing upfront surgery for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into 4 groups: (i) luminal A (ER and/or PR-positive, HER2-negative, Ki67_12), (ii) luminal B (ER and/or PR-positive, HER2-negative, Ki67 > 12), (iii) HER2 (HER2-positive) and (iv) basal-like (triple-negative) disease. Ki67 expression and nodal involvement of IDC with or without DCIS in these groups were compared. RESULTS: The number of patients with luminal A, luminal B, HER2 and basal-like breast cancer were 458, 315, 247 and 128 respectively. Ki-67 was lower in IDC-DCIS than in size-adjusted pure IDC of both luminal A and luminal B subtypes (p = 0.15 and <0.005 respectively). Pure IDC of these biological subtypes were also associated with more advanced lymph node status as compared to IDC-DCIS, although not statistically significant. In HER2 or basal-like tumors, there were no significant difference between pure IDC and IDC-DCIS. CONCLUSION: The presence of co-existing DCIS in IDC predicts lower biological aggressiveness in luminal cancers but not in the conventionally more aggressive HER2-positive and triple-negative subtypes. | - |
dc.language | eng | en_US |
dc.publisher | Churchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast | - |
dc.relation.ispartof | The Breast | en_US |
dc.title | Presence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0960-9776&volume=20&issue=suppl. 1&spage=S39, article no. P182&epage=&date=2011&atitle=Presence+of+an+in-situ+component+predicts+reduced+tumor+aggressiveness+in+luminal+subtype+of+invasive+breast+cancer | - |
dc.identifier.email | Leung, RCY: rolandleung2003@yahoo.com | en_US |
dc.identifier.email | Chiu, J: jfchiu@hkucc.hku.hk | - |
dc.identifier.email | Yau, T: tyaucc@hku.hk | - |
dc.identifier.authority | Yau, T=rp01466 | en_US |
dc.identifier.hkuros | 189002 | en_US |
dc.identifier.hkuros | 198396 | - |
dc.identifier.volume | 20 | en_US |
dc.identifier.issue | suppl. 1 | en_US |
dc.identifier.spage | S39, article no. P182 | en_US |
dc.identifier.epage | S39, article no. P182 | en_US |
dc.description.other | The 12nd International Conference Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 15-19 March 2011. In The Breast, 2011, v. 20, suppl. 1, p. S39, article no. P182 | - |
dc.identifier.issnl | 0960-9776 | - |